Le Lézard
Classified in: Health
Subject: MAT

The Bluntness, Inc. Debuts eBook Revealing Success Secrets To Starting a Cannabis Business in NY


The Bluntness, Inc., today announced the debut of its free business eBook - The Guide to Starting a Cannabis Business - a Comprehensive Go-To Business Primer for Aspiring Cannabis Entrepreneurs

NEW YORK, Sept. 7, 2022 /PRNewswire-PRWeb/ -- The Bluntness, Inc., one of the fastest growing independent digital media companies and 360° lifestyle brands that explores, examines and elevates cannabis & psychedelic culture, community & commerce, today announced the debut of its free business eBook, The Guide to Starting a Cannabis Business.

The Guide to Starting a Cannabis Business, is poised to become the go-to business blueprint for aspiring cannabis entrepreneurs looking to unlock the hidden benefits of planning for success in the highly competitive and highly regulated cannabis industry taking shape in NY and elsewhere.

Developed by The Bluntness' in-house Content Studio, The Guide to Starting a Cannabis Business proves that it is one thing to talk about and cover the cannabis industry and truly another to be an active participant of it - e.g. acquire a license, raise capital, understand the legal complexities & ramifications of compliance - as well as the universal measures that accompany running a successful business of any kind, have a vision, execute goals, establish processes and the steps and stamina necessary to achieve it.

The Guide features insights and expertise from well-respected and successful cannabis entrepreneurs, multi-state operators, policy makers and advocates, among others, providing useful knowledge, guidance and inspiration that aspiring cannabis business owners need to create unique and individual success plans in this rapidly evolving, exciting but challenging industry.

By capturing and sharing real-world advice from those who have built successful medical or recreational cannabis businesses, The Bluntness expertly and painstakingly curates their collective wisdom into one compelling and comprehensive blueprint.

"With adult-use cannabis legalization spreading in the United States and especially in our hometown of New York City, many aspiring cannapreneurs want to know - how to get into the industry and what does it take to make a cannabis business successful?" said Harrison Wise, Chairman and Publisher of The Bluntness, Inc. "To help address these and so many other questions of this nature, our editorial team have examined the regulations, spoken to the policy makers, the advocates, the trailblazers, the investors, the operators, the manufacturers, the cultivators, the legacy community and more, in an effort to curate and compile a comprehensive asset of best practices and guidance ? to reveal proven success strategies and secrets to help aspiring cannabis entrepreneurs navigate and capitalize on this huge opportunity."

Check out a few excerpts from the Guide below:

Download our guide today to find out how to get your business up and running in New York State.

"The Guide to Starting a Cannabis Business will provide educational content, best practices, common mistakes, and other operational insights to people and businesses interested in the budding cannabis industry in emerging markets such as NY, NJ, CT and beyond," added Gregory Frye, Executive Editor, TheBluntness.com. "The individual and collective knowledge and expertise of the people we cover every day are second to none and we felt there was a real need to harness and share that knowledge and expertise in a way that adds value."

"The Guide gives the broader cannabis community a single place to access this information and allows our editorial and content teams to provide the same trusted, reliable content on a larger and more impactful scale," Wise concluded.

The Guide to Starting a Cannabis Business is available for download here.

About The Bluntness
Headquartered in NYC, The Bluntness, Inc., is one of the fastest growing independent digital media companies and 360° lifestyle brand that explores, examines and elevates cannabis & psychedelic culture, community & commerce. Since 2018, The Bluntness has served a sophisticated and engaged audience consisting of millions of motivated, passionate and productive adults who choose to enjoy cannabis and psychedelics as part of a balanced and healthy lifestyle. The Bluntness media's unique properties and assets include the BLUNTNESS/100, a list of the 100 most influential people in cannabis and psychedelics; The Edge and Flow State podcasts; as well as original interviews, video, photography and events covering topics that appeal to diverse demographics. Visit us at: http://www.thebluntness.com.

Media Contact

Lucian Sicard, Wise Collective, Inc., 3479460469, [email protected]

Twitter, Facebook

 

SOURCE The Bluntness, Inc.


These press releases may also interest you

at 05:09
Medical imaging IT and cybersecurity company Sectra (STO: SECT B) is publishing its Annual Report and Sustainability Report for the 2023/2024 fiscal year today. This report also includes the Corporate Governance Report for the same period. The...

at 03:20
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...

at 03:00
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...

at 02:30
SOPHiA GENETICS , a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that Dhiti Omics Technologies, a precision molecular diagnostics service provider in India, is live on the SOPHiA...

at 01:15
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial...

at 01:05
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the Company's Financial and Capital Markets Adviser,...



News published on and distributed by: